Drug Profile
Cetylpyridinium chloride - ARMS Pharmaceutical
Alternative Names: ARMS-I; CPCLatest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator ARMS Pharmaceutical
- Developer ARMS Pharmaceutical; University Hospitals Cleveland Medical Center; University of Toledo
- Class Antiseptics; Antivirals; Disinfectants; Pyridinium compounds; Small molecules
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections; Influenza virus infections
- Discontinued Respiratory tract infections
Most Recent Events
- 27 Oct 2020 Discontinued - Phase-II for Respiratory tract infections in USA (PO)
- 02 Apr 2020 ARMS Pharmaceutical, University Hospitals Cleveland Medical Center and Case Western Reserve University plan the ARMS-I COVID Study in COVID-2019 infections (Prevention, Treatment) in USA (PO) in April 2020
- 07 Mar 2017 Chemical structure information added